ProFoldBio
ProFoldBio combines generative AI with an accelerated wet-lab workflow to design and validate de novo biologics that specifically bind amyloid structures implicated in Alzheimer’s, Parkinson’s, and ATTR amyloidosis. The company advances these precision binders as therapeutics and diagnostics, with a tau fibril program currently in candidate selection. Its browser-based ProFold App offers researchers de novo antibody design, 3D structure visualization, and project management tools for private enterprise deployment.
- Drug Discovery & Therapeutics
- Biotechnology
- Artificial Intelligence
- Healthcare Technology
- Software Only
Funding
Founders
Founder details are not available yet.
Product
Problem
Amyloid diseases, including Alzheimer’s, Parkinson’s, and ATTR amyloidosis, affect over 45 million people globally, yet drug discovery against these targets has been held back by challenging biology and chemistry. Standard approaches struggle to access difficult binding surfaces on amyloid fibrils, and non-specific binders often fail late in development, leading to costly delays and limited therapeutic options.
Solution
ProFoldBio uses generative AI paired with an accelerated laboratory workflow to design and validate novel biologics that recognize specific amyloid structures behind each disease. The company re-engineers amyloids for high-throughput binder discovery and uses proprietary AI models to flag non-specific hits before they reach the bench. Binders are produced and tested in short design-build-test cycles, selecting for polymorph specificity rather than pan-amyloid binding. ProFoldBio advances these precision binders as therapeutics and diagnostics, both in-house and with pharma and biotech partners, and also offers its design platform to external researchers.
Target Audience
Primary customers are pharmaceutical and biotech companies seeking co-development or licensing partnerships for amyloid-targeting therapeutics and diagnostics, as well as academic research groups and enterprise researchers needing AI-driven antibody design and validation tools.
Features
- Generative AI models combined with classical machine learning and physics-based modeling to design binder candidates in silico
- Proprietary amyloid-focused binder libraries tuned to diverse fibril architectures for rapid hit discovery
- Amyloid-tailored validation testing hits against disease-relevant fibril states, selecting for polymorph specificity and functional activity
- Accelerated lab workflow with short design, build, and test cycles to filter out liabilities early
- Browser-based ProFold App featuring de novo antibody design, 3D structure visualization, and project management tools with private enterprise deployments
- Pipeline of four programs: tau fibril (candidate selection), tau FIA (lead optimization), α-synuclein (discovery), and TTR (discovery)